ADVM Key Statistics, Chart & Performance
The current stock price of ADVM is 4.15 USD. In the past month the price increased by 1.72%. In the past year, price decreased by -31.46%.
ADVM Latest News, Press Relases and Analysis
ADVM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.74 | 413.07B | ||
| AMGN | AMGEN INC | 15.42 | 181.50B | ||
| GILD | GILEAD SCIENCES INC | 15.43 | 156.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.8 | 110.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.05 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.21 | 57.71B | ||
| INSM | INSMED INC | N/A | 43.42B | ||
| NTRA | NATERA INC | N/A | 32.22B | ||
| BIIB | BIOGEN INC | 10.79 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 21.35B | ||
| INCY | INCYTE CORP | 16.48 | 20.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About ADVM
Company Profile
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 155 full-time employees. The company went IPO on 2014-07-31. The company discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
Company Info
ADVERUM BIOTECHNOLOGIES INC
100 Cardinal Way
Redwood City CALIFORNIA 94063 US
CEO: Laurent Fischer
Employees: 155
Phone: 16506491004
ADVERUM BIOTECHNOLOGIES INC / ADVM FAQ
What does ADVM do?
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company is headquartered in Redwood City, California and currently employs 155 full-time employees. The company went IPO on 2014-07-31. The company discovers and develops gene therapy product candidates that provide durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD). Its other partnered programs include BGTF-027 (AAV.7m8-L-opsin), a gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.
What is the stock price of ADVERUM BIOTECHNOLOGIES INC today?
The current stock price of ADVM is 4.15 USD. The price increased by 0.24% in the last trading session.
Does ADVM stock pay dividends?
ADVM does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADVM stock?
ADVM has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is ADVERUM BIOTECHNOLOGIES INC (ADVM) stock traded?
ADVM stock is listed on the Nasdaq exchange.
What do analysts say about ADVERUM BIOTECHNOLOGIES INC (ADVM) stock?
12 analysts have analysed ADVM and the average price target is 10.1 USD. This implies a price increase of 143.33% is expected in the next year compared to the current price of 4.15.
Can you provide the market cap for ADVERUM BIOTECHNOLOGIES INC?
ADVERUM BIOTECHNOLOGIES INC (ADVM) has a market capitalization of 87.07M USD. This makes ADVM a Micro Cap stock.
ADVM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ADVM. When comparing the yearly performance of all stocks, ADVM turns out to be only a medium performer in the overall market: it outperformed 66.04% of all stocks.
ADVM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADVM. While ADVM seems to be doing ok healthwise, there are quite some concerns on its profitability.
ADVM Financial Highlights
Over the last trailing twelve months ADVM reported a non-GAAP Earnings per Share(EPS) of -8.58. The EPS decreased by -43.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.49% | ||
| ROE | -181.81% | ||
| Debt/Equity | 0 |
ADVM Forecast & Estimates
12 analysts have analysed ADVM and the average price target is 10.1 USD. This implies a price increase of 143.33% is expected in the next year compared to the current price of 4.15.
For the next year, analysts expect an EPS growth of -5.91% and a revenue growth 1165.78% for ADVM